TY - JOUR
T1 - Different ability of multidrug-resistant and-sensitive counterpart cells to release and capture extracellular vesicles
AU - Sousa, Diana
AU - Lima, Raquel T.
AU - Lopes-Rodrigues, Vanessa
AU - Gonzalez, Esperanza
AU - Royo, Félix
AU - Xavier, Cristina P. R.
AU - Falcón-Pérez, Juan M.
AU - Vasconcelos, M. Helena
N1 - Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/10/26
Y1 - 2021/10/26
N2 - Cancer multidrug resistance (MDR) is one of the main challenges for cancer treatment efficacy. MDR is a phenomenon by which tumor cells become resistant to several unrelated drugs. Some studies have previously described the important role of extracellular vesicles (EVs) in the dissemination of a MDR phenotype. EVs’ cargo may include different players of MDR, such as microRNAS and drug-efflux pumps, which may be transferred from donor MDR cells to recipient drug-sensitive counterparts. The present work aimed to: (i) compare the ability of drug-sensitive and their MDR counterpart cells to release and capture EVs and (ii) study and relate those differences with possible distinct fate of the endocytic pathway in these counterpart cells. Our results showed that MDR cells released more EVs than their drug-sensitive counterparts and also that the drug-sensitive cells captured more EVs than their MDR counterparts. This difference in the release and capture of EVs may be associated with differences in the endocytic pathway between drug-sensitive and MDR cells. Importantly, manipulation of the recycling pathway influenced the response of drug-sensitive cells to doxorubicin treatment.
AB - Cancer multidrug resistance (MDR) is one of the main challenges for cancer treatment efficacy. MDR is a phenomenon by which tumor cells become resistant to several unrelated drugs. Some studies have previously described the important role of extracellular vesicles (EVs) in the dissemination of a MDR phenotype. EVs’ cargo may include different players of MDR, such as microRNAS and drug-efflux pumps, which may be transferred from donor MDR cells to recipient drug-sensitive counterparts. The present work aimed to: (i) compare the ability of drug-sensitive and their MDR counterpart cells to release and capture EVs and (ii) study and relate those differences with possible distinct fate of the endocytic pathway in these counterpart cells. Our results showed that MDR cells released more EVs than their drug-sensitive counterparts and also that the drug-sensitive cells captured more EVs than their MDR counterparts. This difference in the release and capture of EVs may be associated with differences in the endocytic pathway between drug-sensitive and MDR cells. Importantly, manipulation of the recycling pathway influenced the response of drug-sensitive cells to doxorubicin treatment.
KW - Cancer multidrug resistance
KW - Endocytic pathway
KW - Extracellular vesicles
UR - http://www.scopus.com/inward/record.url?scp=85117907370&partnerID=8YFLogxK
U2 - 10.3390/cells10112886
DO - 10.3390/cells10112886
M3 - Article
C2 - 34831110
AN - SCOPUS:85117907370
SN - 2073-4409
VL - 10
JO - Cells
JF - Cells
IS - 11
M1 - 2886
ER -